The sharp selloff in fledgling biopharma and life sciences stocks in the past year or so has not spared RTW Investments. The fund was down more than 9 percent in 2021 and lost another 17.6 percent in January of this year.
Even so, its recent setbacks were not as painful as those suffered by some of its peers, including Perceptive Advisors, which lost 21 percent last year and more than 18 percent this January.
Now
